secwatch / observer

8-K filed October 17, 2025, 7:59 PM ET ticker PHGE CIK 0001739174

regulatory confidence high sentiment positive materiality 0.75

BiomX: FDA clinical hold update – narrow nebulizer queries, no drug concerns; EU enrollment ahead

BiomX Inc.

FDA provided additional narrow questions on third-party nebulizer; no concerns about BX004 drug product.
BiomX believes it has fully addressed the FDA's queries.
European portion of Phase 2b study continues enrollment ahead of plan; topline results on track for Q1 2026.
FDA recognized unmet medical need for chronic Pseudomonas aeruginosa infection in CF and outlined potential Phase 3 pathways.
BiomX plans to incorporate FDA feedback into development; expects End-of-Phase 2 meeting after trial completion.

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-099752
form_type: 8-K
ticker: PHGE
cik: 0001739174
company_name: BiomX Inc.
filed_at: 2025-10-17T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.287383+00:00
generated_at: 2026-05-17T03:24:48.153606+00:00
sec_items: ["8.01"]
event_type: regulatory
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-099752
json_url: https://secwatch.observer/filing/0001213900-25-099752.json
markdown_url: https://secwatch.observer/filing/0001213900-25-099752.md
text_url: https://secwatch.observer/filing/0001213900-25-099752.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390025099752/0001213900-25-099752-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390025099752/ea0261617-8k_biomx.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

LESL

Leslie's regains Nasdaq compliance for minimum market value of publicly held shares

Leslie's, Inc. June 1, 2026, 4:28 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days

Outlook Therapeutics, Inc. June 1, 2026, 9:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

VYGR

FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's

Voyager Therapeutics, Inc. June 1, 2026, 8:00 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

EXFY

Expensify regains Nasdaq minimum bid price compliance

Expensify, Inc. May 29, 2026, 5:15 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SLXN

Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted

Silexion Therapeutics Corp May 29, 2026, 7:00 AM ET regulatory Items 3.03, 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing

RICHTECH ROBOTICS INC. May 28, 2026, 4:49 PM ET regulatory Items 3.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

MNKD

FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29

MANNKIND CORP May 28, 2026, 8:37 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SNAL

Snail receives Nasdaq extension to Sept 22, 2026 to regain listing compliance

Snail, Inc. May 27, 2026, 4:25 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-25-099752

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.